Biosynth stock isn't listed on any public exchange. Learn why the Swiss reagent maker is private and which life-science peers investors watch instead.
Biosynth is not a publicly traded company, so there is no Biosynth stock ticker on the Nasdaq, NYSE, or any other major exchange. The Switzerland-based life-science supplier is privately held and majority-owned by private-equity investors. Investors who want exposure to the same reagent and peptide sector usually turn to listed peers such as GenScript, Bachem, and AsymChem instead.
Why Biosynth Has No Public Stock Ticker
Biosynth supplies research reagents, custom peptides, antibodies, enzymes, and carbohydrates to pharmaceutical, diagnostic, and academic customers worldwide. The company is headquartered in Staad, Switzerland.
In 2021, private-equity firm EQT acquired Biosynth Carbosynth. That deal took the combined business private and removed any path to a public listing under the Biosynth name. As of 2025, no Biosynth shares trade on any major exchange.
Several unrelated companies also use the word "Biosynth" in their names. Always confirm the legal entity and jurisdiction before acting on a ticker symbol you find online.
- Ownership: Private equity and management.
- Ticker: None.
- SEC filings: None, because Biosynth is not a US-listed issuer.
- Investor access: Limited to private transactions, if any.
How to Invest in the Life-Science Reagent Sector Instead
If your goal is exposure to the same end markets Biosynth serves — pharma research, diagnostics, and peptide manufacturing — several publicly traded alternatives exist. Each has different risk, liquidity, and geographic exposure.
Many investors research genscript stock and asymchem stock because both companies compete in gene synthesis, peptides, and CDMO services. Bachem (SIX: BANB) is a pure-play peptide manufacturer listed in Switzerland.
Broader tools and reagents names include Thermo Fisher Scientific (NYSE: TMO), Danaher (NYSE: DHR), Merck KGaA (XETRA: MRK), and Sartorius (XETRA: SRT3). These are large, diversified companies, so Biosynth-style reagent revenue is a small slice of their total business.
| Company | Ticker / Exchange | Primary Focus | Notes |
|---|---|---|---|
| Biosynth | None (private) | Reagents, peptides, antibodies | Not investable via public markets |
| GenScript | 1548.HK | Gene synthesis, peptides, CDMO | Hong Kong-listed; global operations |
| AsymChem | 002821.SZ / 6821.HK | CDMO, small-molecule APIs | Dual-listed in Shenzhen and Hong Kong |
| Bachem | BANB.SW | Peptide APIs and research peptides | Swiss pure-play peptide maker |
| Thermo Fisher | TMO (NYSE) | Lab equipment, reagents, services | Large-cap diversified |
Each of these companies carries sector-specific risks, including regulatory changes, reimbursement pressure, and currency swings. A financial advisor can help you compare them against your goals.
Biosynth's Business Model and Growth
Biosynth makes money by selling specialty reagents and custom synthesis services to pharmaceutical and biotech customers. The company has grown through acquisitions, adding peptide and antibody capabilities to its original carbohydrate and enzyme portfolio.
Private-equity ownership lets Biosynth invest in capacity and acquisitions without quarterly earnings pressure. It also means outside investors cannot buy shares through a standard brokerage account.
For researchers, the relevant question is usually product availability and lead times, not stock price. For investors, the relevant question is whether a comparable public company offers a better risk-adjusted way to own the theme.
What About Biosynth Jobs and Careers?
People searching for biosynth jobs are usually looking at the company's careers page, not its stock. Biosynth hires in Switzerland, the UK, the US, India, and other locations across R&D, manufacturing, quality, and commercial roles.
Because the company is private, it does not publish quarterly earnings or investor presentations. Job candidates and customers can still find product catalogs, technical documentation, and contact details on Biosynth's official website.
Peptide Stocks and the Broader Market
Interest in Biosynth often overlaps with interest in peptide companies more broadly. Investors screen for manufacturers that make GLP-1 intermediates, custom peptides, or research-grade compounds.
AmbioPharm is another private peptide manufacturer with no public ticker. Investors sometimes compare it to listed CDMOs, but its shares are not available on any exchange.
Some investors search for a Chinese peptide supplier and end up on vendor websites rather than brokerage platforms. Those suppliers are typically private, so verify the legal entity before sending funds.
Researchers who order from GenScript use the genscript login portal, while investors track the same company through its Hong Kong-listed shares.
Note that research peptides sold online are often not FDA-approved for human use. Always consult a healthcare professional before using any peptide product, and treat unregulated vendors with caution.
Bottom Line on Biosynth Stock
There is no Biosynth stock to buy because Biosynth is a private company. Any website or message board claiming otherwise is likely confusing Biosynth with a different entity or promoting a scam.
Investors who want exposure to the same sector can research listed peers like GenScript, AsymChem, Bachem, and Thermo Fisher. Each has different risks, and none is a perfect substitute for a private stake in Biosynth.
If you already hold private shares or are offered them through a secondary market, review the paperwork with a qualified financial advisor. Private-company shares are illiquid and can be difficult to value.
Frequently Asked Questions
Is Biosynth a publicly traded company?
No. Biosynth is privately held and backed by private-equity investors, so it has no stock ticker on the Nasdaq, NYSE, or any other exchange. The company does not file quarterly earnings reports for public shareholders.
What stock is similar to Biosynth?
Investors often compare Biosynth to listed life-science suppliers such as Bachem (BANB.SW), GenScript (1548.HK), and AsymChem (002821.SZ). Thermo Fisher (TMO) and Danaher (DHR) offer broader exposure to lab reagents and tools. None of these companies is a perfect match for Biosynth's private business.
Can I buy Biosynth shares on the secondary market?
Private-company shares sometimes change hands through secondary transactions, but they are illiquid and usually restricted to accredited investors. Biosynth does not publicly offer shares to retail investors. Consult a financial advisor before participating in any private-share deal.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.